住院患者使用利伐沙班时凝血酶原时间与出血风险的关联
这项单中心回顾性队列研究纳入199例住院期间使用利伐沙班并在给药后24小时内检测凝血酶原时间(PT)的成人患者,比较出血组与未出血组。结果显示PT≥30秒者出血事件率显著高于PT<30秒者(38.7%对17.3%,p=0.0067),多变量回归显示PT≥30秒与约3倍出血风险相关(OR 3.25;95%CI 1.09-9.66),低白蛋白血症亦为出血的阳性预测因素,而血栓栓塞事件组间无显著差异。
要点
- 利伐沙班用药后PT≥30秒与住院患者出血风险升高约3倍相关。
- 低白蛋白血症是该人群出血风险的独立阳性预测因素。
- PT≥30秒与<30秒两组间血栓栓塞事件无显著差异。
核心结论
- 住院患者使用利伐沙班并检测凝血功能时,PT≥30秒与更高的出血风险相关。
- 低白蛋白血症在该人群中亦与出血相关。
研究设计与样本
- 单中心回顾性队列研究,纳入在指定23个月期间使用利伐沙班后24小时内检测PT的成人住院患者。
- 共199例患者符合纳入标准,其中41例发生出血事件。
- 采用多变量logistic回归模型量化PT与出血事件的关联,并校正白蛋白水平及非甾体抗炎药和/或抗血小板药物使用。
主要发现
- PT≥30秒组总体出血事件率为38.7%,PT<30秒组为17.3%,差异有统计学意义(p=0.0067)。
- 多变量回归显示PT≥30秒与约3倍出血风险相关(OR 3.25;95%CI 1.09-9.66)。
- 低白蛋白血症为出血风险的阳性预测因素。
- 血栓栓塞事件在组间无显著差异。
关键数值与推荐
- PT≥30秒作为出血风险升高的关联阈值(OR 3.25;95%CI 1.09-9.66)。
- 出血事件率:PT≥30秒组38.7%,PT<30秒组17.3%(p=0.0067)。
临床怎么用
- 对住院使用利伐沙班的患者,若PT≥30秒应警惕出血风险升高。
- 关注低白蛋白血症患者使用利伐沙班时的出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Results of an investigation of the pharmacodynamic effect of rivaroxaban anticoagulation, as measured by prothrombin time (PT), on bleeding risk and other outcomes in hospitalized patients are reported. METHODS: In a single-center retrospective cohort study, adult inpatients who had a PT measured within 24 hours after rivaroxaban administration during a designated 23-month period were identified. Patients who experienced in-hospital bleeding events were compared with those who did not. A multivariable logistic regression model was used to quantify the association between PT and bleeding events while adjusting for albumin levels and use of nonsteroidal antiinflammatory drugs and/or antiplatelet agents. Thromboembolic events were assessed as a secondary outcome. RESULTS: A total of 199 patients met the criteria for inclusion in the analysis; 41 experienced a bleeding event. Among patients with a PT of ≥30 seconds versus a PT of <30 seconds, the overall rate of bleeding events was significantly higher (38.7% versus 17.3%, p = 0.0067). Results of multivariable regression modeling showed that a PT of ≥30 seconds correlated with an approximately 3-fold higher bleeding risk (odds ratio, 3.25; 95% confidence interval, 1.09-9.66). Hypoalbuminemia was also a positive predictor of bleeding risk. There was no significant between-group difference in thromboembolic events. CONCLUSION: In hospitalized patients receiving rivaroxaban who had coagulation tests performed, a PT of ≥30 seconds was associated with a higher risk of bleeding. Hypoalbuminemia was also associated with bleeding in this population.
引用
- Woodruff AE, Wovkulich MM, Mogle BT, et al. Association between prothrombin time and bleeding in hospitalized patients receiving rivaroxaban. Am J Health Syst Pharm. 2018. PMID: 30049684. doi:10.2146/ajhp180031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。